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Rheumatoid arthritis (RA) has been identified as an independent cardiovascular risk factor.
The importance of risk factors such as hypertension and hyperlipidemia in the generation of
atherosclerosis in RA patients is unclear. This study analyzed clinical parameters associ-
ated with carotid intima media thickness (cIMT) in patients with RA.
Methods
Subjects with RA and healthy controls without RA, both without known cardiovascular dis-
ease, were included. Participants underwent a standard physical examination and labora-
tory measurements including a lipid profile. cIMT was measured semi-automatically by
ultrasound.
Results
In total 243 RA patients and 117 controls were included. The median RA disease duration
was 7 years (IQR 2–14 years). The median DAS28 was 2.4 (IQR 1.6–3.2) and 114 (50.4%)
of the RA patients were in remission. The presence of RA and cIMT were not associated
(univariate analysis). Multivariable regression analysis showed that cIMT in RA patients
was associated with age (B = 0.006, P<0.001) and systolic blood pressure (B = 0.003, P =
0.003). In controls, cIMT was associated with age (B = 0.006, P<0.001) and smoking (B =
0.097, P = 0.001).
PLOS ONE | DOI:10.1371/journal.pone.0140844 October 20, 2015 1 / 11
OPEN ACCESS
Citation: van Breukelen—van der Stoep DF, van
Zeben D, Klop B, van de Geijn G-JM, Janssen HJW,
Hazes MJMW, et al. (2015) Association of
Cardiovascular Risk Factors with Carotid Intima
Media Thickness in Patients with Rheumatoid
Arthritis with Low Disease Activity Compared to
Controls: A Cross-Sectional Study. PLoS ONE 10
(10): e0140844. doi:10.1371/journal.pone.0140844
Editor: Eliseo A Eugenin, Rutgers University,
UNITED STATES
Received: June 1, 2015
Accepted: October 1, 2015
Published: October 20, 2015
Copyright: © 2015 van Breukelen—van der Stoep
et al. This is an open access article distributed under
the terms of the Creative Commons Attribution
License, which permits unrestricted use, distribution,
and reproduction in any medium, provided the
original author and source are credited.
Data Availability Statement: Data are available from
Dryad (doi:10.5061/dryad.hh3j7).
Funding: This study consists of data from two
studies. One study, the FRANCIS study, received
financial support from the Sint Francicsus Research
Fund and the Stichting Coolsingel Rotterdam. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Conclusion
cIMT values were similar between RA patients and controls. Hypertension was strongly
associated with cIMT in RA patients. After adjustment, no association between cIMT and
specific RA disease characteristics was found in this well treated RA cohort.
Introduction
Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease of unknown etiology,
affecting ~1% of the adult general population [1, 2]. Patients with RA have a higher all cause
mortality risk than the general population and the leading cause of death is cardiovascular dis-
ease (CVD) [3–5]. The evidence of the excess cardiovascular risk in rheumatoid arthritis (RA)
has been well described [3, 5–9] and the presence of RA can be considered an independent risk
factor for CVD [7, 10]. The prevalence of CVD in patients with RA is as high as in patients
with type 2 diabetes mellitus [7, 11]. Since inflammation is a key event in the development of
atherosclerosis [12–14] it has been proposed that the increased inflammatory state of patients
with RA explains, at least in part, the increased cardiovascular risk [8, 10, 15–17]. Several RA
specific risk factors such as disease activity, inflammatory markers and anti-CCP have been
associated with an increased carotid intima media thickness (cIMT) and CVD risk. A recent
study by Barbarroja et al. showed that anti-CCP antibodies act as direct inductors of the pro-
oxidative status and the inflammatory and atherogenic profile of lymphocytes, monocytes and
neutrophils in RA [18]. In line with this report, Vázquez et al. showed an association between
anti-CCP levels and CRP levels with an increased cIMT and CVD risk [19]. Moreover, tradi-
tional risk factors such as hypertension, hyperlipidemia, smoking and overweight are also
highly prevalent among RA patients [20, 21], and several studies have shown a significant
underdiagnosis and undertreatment of these traditional risk factors in RA [22, 23].
The cIMT measured by ultrasound is a surrogate marker of atherosclerosis and the most
widely used non invasive imaging method to assess atherosclerosis and CVD risk. A higher
cIMT reflects a (pre-) atherogenic condition and is predictive for future cardiovascular events
[24, 25]. Several studies have shown an increased cIMT in RA patients, even early in the course
of the disease [26–30]. Traditional risk factors may also play a role besides the inflammatory
state in RA. Unfortunately, the association between traditional risk factors and cIMT in RA
patients is still unclear [31]. Increasing evidence suggests that a cumulative number of tradi-
tional CVD risk factors contributes to the higher CVD risk in RA [32]. The aim of this study
was to investigate which factors are associated to cIMT in RA patients in comparison to
controls.
Materials and Methods
Study design and subjects
A cross-sectional study was carried out in patients with RA and controls to determine the dif-
ferences in the relationship between cIMT and clinical factors. The study was carried out
between July 2009 and February 2013 at the Diabetes and Vascular Centre and the outpatient
clinic of Rheumatology of the Sint Franciscus Gasthuis, Rotterdam, the Netherlands. All
patients with RA in this report were participants in the FRANCIS study, an open label random-
ized clinical trial to investigate the effectiveness of strict treatment of cardiovascular risk factors
in RA (The Dutch Trialregister, NTR3873; ABR no. NL32669.101.10). RA patients attending
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the outpatient clinic from the Department of Rheumatology were asked to participate in the
FRANCIS study. Inclusion criteria were the presence of RA and an age70 years. Exclusion
criteria were the presence of diabetes mellitus (DM) or CVD. CVD was defined as a docu-
mented history of myocardial infarction, cerebrovascular event, amputation due to peripheral
artery disease, intermittent claudication, or a prior percutaneus transluminal coronary angio-
plasty (TCA) or coronary artery bypass graft (CABG). In addition, kidney disease defined as an
MDRD< 40 was an exclusion criterium. Only patients with a CVD risk<10% according to the
2009 version of the SCORE model were randomized. Patients aged over 65 years were classified
as 65 years old in order to be able to use the SCORE model. Patients with a CVD risk10%
were followed in a separate cohort (“high risk cohort”). For the current analysis, baseline data
from both randomized patients and patients in the high risk cohort were used. The RA patients
were treated by their own rheumatologists according to a treat-to-target principle, aiming for
disease remission (DAS28<2.6). RA was defined by the ACR ‘87 criteria [33]. Unmatched con-
trol subjects were non-RA patients followed in a separate observational study (ABR no.
NL29910.101.09) from our department. They were recruited from the outpatient clinic of the
Diabetes and Vascular Center of the Sint Franciscus Gasthuis in Rotterdam and underwent
measurements identical to the RA patients of the FRANCIS study [34]. Exclusion criteria for
the control group were also the presence of DM, CVD and/or kidney disease. All controls ful-
filling the age limit of70 years were included in this analysis. In addition, RA patients and
controls who used statins and/or anti-hypertensives were excluded. Controls with a CRP>10
mg/L were excluded from the analysis. Anthropometric characteristics i.e. height, weight, waist
circumference and blood pressure were obtained as well as a detailed medical history and the
use of medication. All subjects provided written informed consent. The studies were approved
by the independent Regional Medical Ethical Committee Rotterdam of the Maasstad Hospital,
the Netherlands.
Rheumatoid arthritis disease activity
Rheumatoid arthritis disease activity was assessed by using the Disease Activity Score with 28
joints counted (DAS28). This score included swollen joint count (28), tender joint count (28),
VAS (0–100 scale) indicating pain/discomfort due to RA, and the erythrocyte sedimentation
rate (ESR). We also calculated disease activity with C-reactive protein (CRP) instead of ESR
(DAS28CRP),
Laboratory measurements
A standardized set of measurements was performed in each subject. Laboratory parameters
were determined at the Department of Clinical Chemistry, Sint Franciscus Gasthuis, according
to standard procedures. Renal and liver function tests as well as glucose, CRP, total cholesterol,
HDL-C and triglycerides (TG) were measured using Synchron LX-20 and DxC analyzers
(Beckman Coulter, Anaheim CA, USA) (34, 35). LDL-C was calculated using the Friedewald
formula if TG were below 4.60 mmol/l. Apolipoprotein (apo) AI and apo B were determined in
serum by rate nephelometry using IMMAGE with commercially available kits (Beckman Coul-
ter, Anaheim CA, USA) [31,32]. In the case of RA patients, blood samples were obtained fol-
lowing the strict protocol of the FRANCIS study. Samples from control subjects were drawn
with less strict criteria.
Intima media thickness of the carotid arteries
Carotid ultrasound scans were carried out using the ART-LAB (Esaote, Italy) by trained and
experienced sonographers as described earlier [34, 35]. Ultrasound scans were performed with
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the patients lying in a supine position with the head resting comfortably and the neck slightly
hyperextended and rotated in the opposite direction of the probe. The ultrasound images were
obtained of the distal 1 cm of the far wall of each common carotid artery (CCA) using B-mode
ultrasound producing two echogenic lines. These lines represent the combined thickness of the
intima and media layers of the arterial wall. Each CCA was imaged in three different projec-
tions: CCA right side 90-120-150 and CCA left side 210-240-270 degrees. The segments were
measured semi-automated in triplicate. In some patients cIMT measurements were only partly
available due to technical difficulties. In these cases, the mean cIMT was only calculated if at
least measurements at two different angles per side were available.
Statistics
Data are given as mean ± standard deviation (SD) unless stated otherwise. Differences between
groups were determined using the unpaired Student’s t-test or Chi-square test, where appropri-
ate. In case of skewed variables (DAS28(-CRP) and TG), the Mann-Whitney U test was used
for comparisons between groups. For statistical analysis, cIMT was defined as the mean of the
six individual measurements. Multivariable linear regression analysis was used to identify fac-
tors associated with cIMT in RA patients and controls. Covariables entered into the regression
analysis were: age, sex, systolic blood pressure, waist circumference, smoking habit, glucose,
apo AI, apo B, total cholesterol, HDL-C, LDL-C, TG, glucose, creatinin and CRP. For RA
patients, the presence of rheumatoid factor and anti-CCP, erosive disease, disease duration,
DAS28CRP, DAS28 and the use of methotrexate and biologicals were added to the model. Cov-
ariables showing a P<0.10 in the univariate analysis were entered in the multivariable analysis.
In order to create comparable models for RA patients and controls, a separate analysis with
and without RA disease duration was performed for RA patients. In the case that two or more
related parameters were highly correlated (multicollinearity), only one was selected for the
multivariable analysis. As a result, waist circumference was selected instead of BMI; systolic
blood pressure was selected instead of diastolic blood pressure; and LDL-C was chosen above
apo B or TG. Significant co-variables were investigated for interaction. The multivariable anal-
ysis included age, sex, smoking, waist circumference, systolic blood pressure and LDL-C. The
association between glucose and cIMT was analyzed separately because it was unknown which
of the control subjects had their blood samples taken after an overnight fast. All statistical anal-
yses were performed using PASW statistics version 18.0 (IBM SPSS Statistics, New York,
United States). P-values below 0.05 (two sided) were considered statistically significant.
Results
General Characteristics
243 RA patients and 117 controls were included. General characteristics of RA patients and
controls are shown in Table 1. Both groups were comparable regarding age, gender, lipid pro-
file, waist circumference, and cIMT. There were more current smokers among RA patients
compared to controls. RA patients had a significantly higher body mass index (BMI) and sys-
tolic blood pressure (Table 1).
The median RA disease duration for RA patients was 7 years (IQR 2–14 years). In total, 107
patients (44.0%) used NSAIDS, 186 (76.5%) RA patients used methotrexate and 96 (39.5%)
used an anti-TNFα or other biological agent. Of the 96 patients with a biological agent, 25
(26%) used no methotrexate and 71 (74%) used a combination of methotrexate and a
biological.
The median DAS28 was 2.4 (IQR 1.6–3.2). In total, 114 (50.4%) of the RA patients had a
DAS28<2.6 implying disease remission, 48 (21.2%) had low disease activity (DAS28 2.6–3.1),
cIMT Associated CVD Risk Factors: RA vs. Controls
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47 (20.7%) had moderate disease activity (DAS28 3.1–5.1) and 17 (7.5%) had high disease
activity (DAS28 5.1). When applying DAS28CRP, the results were similar: the median
DAS28CRP was 2.2 (IQR 1.6–2.9), 113 (58.8%) had disease remission, 39 (17.3%) had low dis-
ease activity, 40 (17.7%) had moderate disease activity and 14 (6.2%) had high disease activity.
cIMT did not differ between RA groups based on their disease activity (data not shown).
Univariate analysis
To identify the covariables associated with cIMT, univariate regression analysis was carried out
in RA patients, controls and the combined patient and control group (Table 2). In all groups
age, systolic blood pressure, LDL-C and apo B showed a significant association with cIMT. Fur-
thermore, in controls, current smoking was significantly associated with cIMT. In RA patients
male gender, BMI, waist circumference, TG, glucose and disease duration were significantly
associated with cIMT. The correlation coefficient between RA disease duration and age was
0.262. A trend towards a positive association between anti-CCP positivity and cIMT was
observed (B = 0.033(-0.044–0.070); P = 0.078) (Table 2). When these univariate analyses
were performed only in RA patients not using biologicals, the associations between cIMT and
anti-CCP positivity, disease duration, glucose and TG were no longer statistically significant
(data not shown). Other parameters showed similar associations as in the total RA group.
Table 1. General Characteristics.
RA-patients Controls P-value
n = 243 n = 117
Male 79 (32.5%) 46 (39.3%) 0.204
Age (yrs) 51.8±11.6 50.0±12.1 0.186
Current smoker (n,%) 54 (22.2%) 16 (13.7%) 0.051
Weight (kg) 76.3±14.4 75.3±14.5 0.520
BMI (kg/m2) 26.1±4.3 24.9±3.7 0.006
Systolic blood pressure (mmHg) 129±18 124±13 0.004
Waist circumference (cm) 93±14 90±12 0.054
Total cholesterol (mmol/l) 5.42±1.08 5.60±1.17 0.147
LDL-C (mmol/l) 3.36±1.02 3.46±1.00 0.372
HDL-C (mmol/l) 1.54±0.51 1.55±0.43 0.894
TG (mmol/l)* 1.03 (0.72–1.42) 1.12 (0.74–1.61) 0.182
Apo AI (g/l) 1.71±0.36 1.65±0.32 0.099
Apo B (g/l) 1.00±0.26 1.04±0.30 0.192
Glucose (mmol/l) 5.40±0.53 5.16±0.89 0.002
C-reactive protein (mg/l)* 2.00 (1.00–5.00) 1.00 (1.00–2.75) <0.001
cIMT (mm) 0.556±0.120 0.573±0.134 0.220
Rheumatoid Factor Positive (n,%) 150 (61.7%)** NA
Anti-CCP positivity (n,%) 142 (58.4%)*** NA
BMI = body mass index TG = triglycerides; Apo = apolipoprotein; cIMT = carotid intima media thickness
Data presented as mean ± standard deviation or n (%) unless stated otherwise.
* Data presented as median (interquartile range). Difference between groups tested with the Mann-Whitney U test.
** data available in 235 patients.
*** data available in 204 patients
NA, not available
doi:10.1371/journal.pone.0140844.t001
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Multivariable analysis
Multivariable regression analysis with identified covariables associated with cIMT, was per-
formed in RA patients, controls and in both groups combined (Table 3). In controls cIMT was
significantly associated with age and current smoking and in RA patients with age and systolic
blood pressure. These results remained unchanged after including glucose in the analysis. In
RA patients, additional multivariable analyses including RA disease duration alone and com-
bined with anti-CCP were performed (Table 4). The addition of RA disease activity and anti-
CCP positivity, alone or combined, did not improve the predictive power of the original multi-
variable model (Table 4). Multivariable analysis in only those RA patients not using biological
therapy showed comparable results.
Discussion
Surprisingly, cIMT in RA patients was similar to the cIMT of control subjects without RA,
which is in contrast to other studies, showing increased cIMT in RA patients even early in the
course of the disease [29, 30, 32, 36–38]. It is even more surprising since in our study RA
patients had a higher BMI, systolic blood pressure, glucose and CRP and, a larger percentage of
RA patients smoked compared to controls.
Table 2. Univariate regression analysis identifying covariables associated with cIMT.
Variable Controls n = 117 RA patients n = 243 Total population n = 360
B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value
Age (yr) 0.006 (0.004–0.007) <0.001 0.006 (0.005–0.007) <0.001 0.006 (0.005–0.007) <0.001
Male sex 0.021 (-0.029–0.071) 0,243 0.050 (0.018–0.082) 0.002 0.041 (0.014–0.068) 0.003
Smoking 0.097 (0.028–0.166) 0.006 0.016 (-0.021–0.053) 0.403 0.034 (0.001–0.067) 0.044
BMI (kg/m2) 0.005 (-0.002–0.012) 0.139 0.005 (0.001–0.008) 0.010 0.004 (0.001–0.007) 0.006
Waist (cm) 0.002 (0.000–0.004) 0.101 0.002 (0.001–0.003) <0.001 0.002 (0.001–0.003) <0.001
BPs (mmHg) 0.002 (0.001–0.004) 0.009 0.003 (0.002–0.004) <0.001 0.003 (0.002–0.003) <0.001
BPd (mmHg) 0.000 (-0.003–0.003) 0.963 0.004 (0.002–0.005) <0.001 0.003 (0.001–0.004) <0.001
LDL-C (mmol/l) 0.043 (0.019–0.066) <0.001 0.034 (0.020–0.049) <0.001 0.037 (0.025–0.050) <0.001
HDL-C (mmol/L) -0.010 (-0.066–0.047) 0.740 -0.010 (-0.040–0.020) 0.511 -0.010 (-0.037–0.017) 0.476
Apo AI (g/l) 0.013 (-0.065–0.091) 0.750 -0.016 (-0.059–0.027) 0.473 -0.010 (-0.048–0.028) 0.610
Apo B (g/l) 0.114 (0.034–0.194) 0.005 0,131 (0.075–0.187) <0.001 0.126 (0.081–0.172) <0.001
TG (mmol/l)* 0.013 (-0.020–0.045) 0.441 0.026 (0.003–0.049) 0.026 0.022 (0.003–0.040) 0.022
Glucose (mmol/l)* 0.009 (-0.019–0.036) 0.536 0.044 (0.016–0.072) 0.002 0.021 (0.001–0.040) 0.029
CRP (mg/dl) -0.000 (-0.014–0.014) 0.964 0.001 (-0.001–0.003) 0.504 0.000 (-0.002–0.002) 0.731
Creatinin (umol/l) 0.001 (-0.001–0.003) 0.549 0.002 (0.001–0.003) 0.002 0.001 (0.001–0.003) 0.002
Absence of RA - - - - 0.017 (-0.010–0.045) 0.220
Anti-CCP - - 0.033 (-0.004–0.070) 0.078
Rheumatoid factor - - 0.020 (-0.013–0.053) 0.231
Erosive Disease - - 0.020 (-0.011–0.051) 0.212
DAS28 - - 0.005 (-0.009–0.019) 0.494
DAS28CRP - - -0.001 (-0.017–0.015) 0.902
Disease duration - - 0.002 (0.001–0.004) 0.012
Methotrexate - - 0.001 (-0.036–0.037) 0.976
Biological agents - - -0.07 (-0.039–0.024) 0.651
RA = Rheumatoid arthritis, BPs = systolic blood pressure, BPd = diastolic blood pressure, TG = triglycerides, DAS28 = RA disease activity score 28 joints
doi:10.1371/journal.pone.0140844.t002
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A post hoc sample size calculation showed that our sample sizes of 243 RA-patients and 117
control patients are not sufficiently large to support the presence of a significant difference in
mean cIMT between the groups with 80% power. However, considering that the difference in
mean cIMT we found (0.017) cannot be considered clinically meaningful, one would need to
include (at least) 270 RA and control patients (at an equivalence margin of 0.05; or 68 patients
at an equivalence margin of 0.10) to support that a difference in cIMT is absent. In summary,
our sample sizes are sufficiently large to support that a clinically meaningful difference in
cIMT in our study is absent, with 90% power.
One of the reasons for this difference with other studies may be the relatively low disease
activity in our RA patients. A higher RA disease activity results in an increased cardiovascular
risk. The RA disease activity in our study was low with a total of 70% of RA patients in clinical
remission or with low disease activity, which may have had a beneficial effect on cIMT. When
we compared cIMT in RA patients with disease remission or low disease activity with cIMT in
RA patient with moderate or high disease activity, no differences in cIMT were found. This
may be due in part to the small proportion of patients with moderate to high disease activity.
Table 3. Multivariable regression analysis with identified covariables associated with cIMT.
Variable Controls n = 117 RA patients n = 243 Total population n = 360
R2 = 0.321 R2 = 0.391 R2 = 0.347
B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value
Age (yr) 0.005 (0.003–0.007) <0.001 0.005 (0.004–0.006) <0.001 0.005 (0.004–0.006) <0.001
Male sex 0.010 (-0.037–0.056) 0.678 0.013 (-0.014–0.040) 0.336 0.015 (-0.008–0.038) 0.201
Smoking 0.101 (0.041–0.162) 0.001 0.019 (-0.011–0.049) 0.207 0.034 (0.007–0.061) 0.014
Waist (cm) 0.002 (0.000–0.004) 0.127 0.001 (0.000–0.002) 0.142 0.001 (0.000–0.002) 0.106
BPs (mmHg) 0.001 (-0.001–0.002) 0.488 0.001 (0.000–0.002) 0.003 0.001 (0.000–0.002) 0.012
LDL-C (mmol/l) 0.009 (-0.016–0.034) 0.467 0.007 (-0.006–0.020) 0.270 0.009 (-0.003–0.020) 0.143
Apo B (g/l) ** ** **
RA = Rheumatoid arthritis, BPs = systolic blood pressure, Apo = apolipoprotein
** When using apoB instead of LDL similar results were found.
doi:10.1371/journal.pone.0140844.t003
Table 4. Multivariable regression analysis including RA disease characteristics.
Variable RA patients n = 243 RA patients n = 243
R2 = 0.39 R2 = 0.40
B (95% CI) P-value B (95% CI) P-value
Age (yr) 0.005 (0.004–0.006) <0.001 0.005 (0.004–0.007) <0.001
Male sex 0.005 (-0.016–0.039) 0.409 0.005 (-0.026–0.035) 0.786
Smoking 0.019 (-0.011–0.049) 0.212 0.020 (-0.02–0.053) 0.220
Waist (cm) 0.001 (0.000–0.002) 0.156 0.001 (0.000–0.002) 0.216
BPs (mmHg) 0.001 (0.000–0.002) 0.002 0.001 (0.000–0.000) 0.005
LDL-C (mmol/l) 0.007 (0.006–0.020) 0.282 0.007 (-0.008–0.021) 0.365
RA disease duration (yrs) 0.000 (-0.002–0.001) 0.579 0.000 (-0.002–0.002) 0.792
Anti-CCP - - 0.007 (-0.024–0.037) 0.661
RA = Rheumatoid Arthritis, BPs = systolic blood pressure
doi:10.1371/journal.pone.0140844.t004
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Our outpatient clinic of Rheumatology is a large outpatient clinic that consists of a large and
representative sample of RA patients in the Netherlands. At the outpatient clinic, a structured
tight control regimen of RA disease activity is carried out reflecting the present situation in the
Netherlands. Therefore, we believe that the sample of RA patients in this study is representative
for the general Dutch RA population, although the results may not apply to RA patients with
higher average disease activity. A meta analysis by Ambrosino et al. reported outcomes of 59
studies on cIMT in RA compared to controls [30]. Not all studies included information on dis-
ease activity, but the mean DAS28 of those studies reporting disease activity ranged from 2.6 to
6.2, which is higher than our reported median DAS28 of 2.4. Of those 59 studies, 51 reported
an increased cIMT in RA patients compared to controls [30]. Only 2 studies reported DAS28
levels<3.0 showing conflicting results concerning differences in cIMT in RA compared to con-
trols [39, 40]. The same meta-analysis by Ambrosino showed that a higher inflammatory status
(DAS28, CRP, ESR) was associated with an increased cIMT [30].
Besides disease activity, several RA specific risk factors, such as the presence of rheumatoid
factor, anti-CCP and erosive disease, are considered risk factors for atherosclerosis. They are all
surrogate markers for the inflammatory burden since the presence of reumatoid factor and/or
anti-CCP often results in a higher disease activity. Also erosive disease occurs mostly in
patients with long periods of uncontrolled disease activity. In our cohort with generally a low
disease activity, rheumatoid factor and anti-CCP positivity were not associated with cIMT in
the multivariable model. These results are in line with several other studies that could not dem-
onstrate an association between these parameters and cIMT [37, 39]. A limitation of our study
was that only qualitative data on rheumatoid factor and anti-CCP were available, since these
characteristics were not re-tested at the time of inclusion. Recently, an in vitro study showed a
positive correlation between the level of anti-CCPs and overexpression of thrombotic, inflam-
matory and pro-oxidative markers in leukocytes [18]. We did find a crude (univariate) associa-
tion between disease duration and cIMT, but this association was no longer significant in the
multivariable model. This is in line with a recent publication by Arts et al who found that the
risk of CVD in RA patients was not increased after 10 years of disease duration when compared
to the first 10 years [40]. Data on the association between cIMT and RA disease duration are
conflicting since several other studies reported a positive association between cIMT and RA
disease duration [37, 41, 42].
Traditional cardiovascular risk factors such as smoking, overweight, hyperlipidemia and
hypertension are highly prevalent in RA patients and can be easily treated by lifestyle and phar-
macological interventions. Nevertheless, underdiagnosis and undertreatment of these risk fac-
tors in RA patients have been described [22, 23, 43]. An association between cIMT and blood
pressure both in the general population and in RA patients has been described previously [17,
27, 44–46]. In the present paper, regression analyses underline the association of systolic blood
pressure on cIMT in RA patients. These data underscore the importance of adequate blood
pressure regulation in RA.
No association between cIMT and lipid levels was found. Hyperlipidemia was strongly asso-
ciated to cIMT in the univariate analysis, but it was no longer significant in the multivariable
analysis after adjustment for other covariables. In contrast to the association found between
smoking and cIMT in controls, no association between smoking and cIMT in RA patients was
found. This is in line with earlier results reported by Gonzalez et al., who found a weaker asso-
ciation between smoking and CVD risk in RA patients than in non-RA patients [47].
In conclusion, in this RA cohort with relatively low disease activity, cIMT was not increased
compared to controls and cIMT was not associated with RA disease characteristics. Hyperten-
sion was strongly associated with cIMT in RA patients. In light of these results and based on
cIMT Associated CVD Risk Factors: RA vs. Controls
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findings from other studies, treatment of hypertension and other traditional CVD risk factors
in RA seems warranted to reduce cardiovascular risk in RA.
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